🧪 What is genomics
The genome is the complete set of an organism's DNA — the “instruction manual” of our biology. Sequencing it reveals predisposition to diseases, drug responses, and hereditary traits.
Greece has a unique genetic profile. The population is relatively homogeneous, with characteristics not found in other databases. This makes the Greek database invaluable for research.
Prevention
Identifying risk for cancer, diabetes, heart disease
📖 Read more: Digital Euro: What Will Change in Payments in Greece
Pharmacogenomics
The right drug at the right dose for each person
Rare diseases
Diagnosing hereditary conditions in children
📖 Read more: Digital Government: Record Transactions 2026
🏛️ How it will operate
The GIHG will collect samples with citizens' consent through the National Health System. Each participant will receive a report with key findings. The anonymized data will feed research and public health policies.
📖 Read more: E-Invoicing: What Changes for Businesses in Greece in 2026
The cost of sequencing has dropped dramatically: from $3 billion in 2003 to under $200 today. This makes the target of 100,000 genomes by 2030 feasible.
⚠️ About privacy
Genetic data is the most personal data there is. GDPR and specific legislation will ensure that no one can be identified from the research data. Access will be granted only for approved research.
📖 Read more: Gut Microchip: Intestine Monitoring in a Pill
🌍 Greece and Europe
The GIHG is part of the European 1+ Million Genomes Initiative. The EU aims to create a pan-European genomic database for better research, faster diagnosis, and personalized treatments.
For Greece, this means jobs for bioinformaticians, geneticists, and data scientists. It also attracts investments from pharma companies looking for data for clinical trials.
OnOff Health
We follow developments in digital health and biotechnology in Greece.
